Crescent Biopharma (CBIO)
NASDAQ:CBIO
Top Page
Crescent Biopharma
(NASDAQ:CBIO)
Select Model
Select Model
Rating:50Neutral
Price Target:
$18.50
▲(0.98% Upside)
Action:ReiteratedDate:03/29/26
The score is held down primarily by weak financial performance (large losses and persistent cash burn). Technicals provide a partial offset with a strong uptrend, though momentum is overbought. Valuation remains challenged because the company is unprofitable and offers no indicated dividend support.
Positive Factors
Recapitalized Balance Sheet
A materially stronger 2025 balance sheet with very low leverage and ~ $203M equity materially improves solvency and near-term financial flexibility. This recapitalization reduces immediate refinancing risk and provides a durable runway to pursue R&D or partnerships over coming quarters.
Negative Factors
Severe Revenue Decline
A ~64.5% revenue drop indicates weak commercial traction or discontinued revenue sources, undermining the company’s ability to leverage fixed costs. Such structural revenue erosion raises sustained growth uncertainty and prolongs dependency on external capital to fund operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Recapitalized Balance Sheet
A materially stronger 2025 balance sheet with very low leverage and ~ $203M equity materially improves solvency and near-term financial flexibility. This recapitalization reduces immediate refinancing risk and provides a durable runway to pursue R&D or partnerships over coming quarters.
Read all positive factors
Crescent Biopharma (CBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$504.84M
Dividend YieldN/A
Average Volume (3M)145.41K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue Growth-100.00%
EPS Growth-0.58%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.01
Shares Outstanding27,556,767
10 Day Avg. Volume163,515
30 Day Avg. Volume145,412
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)6.08
Price to Sales (P/S)113.89
P/FCF Ratio-17.05
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue7.60
Enterprise Value/Gross Profit7.92
Enterprise Value/Ebitda-2.13
Forecast
1Y Price Target
$28.50Price Target Upside55.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.21
Revenue Forecast (FY)$3.88M
Crescent Biopharma Business Overview & Revenue Model
Company Description
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company ha...
Crescent Biopharma Earnings Call Summary
Earnings Call Date:May 06, 2024
(Q1-2024)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The earnings call revealed challenges with the Phase III trial not meeting its primary endpoint, leading to financial and strategic reassessments. However, there is a commitment to further analyze the rich data collected and ongoing trials continue to explore the potential of uproleselan in AML treatment.Positive Updates
Low Discontinuation Rate
The study had a low discontinuation rate of 3%, indicating good patient retention and adherence to the trial protocol.
Negative Updates
Phase III Study Did Not Meet Primary Endpoint
The pivotal Phase III study of uproleselan did not achieve a statistically significant improvement in overall survival in the intent-to-treat population.
Read all updates
Q1-2024 Updates
Positive
Negative
Low Discontinuation Rate
The study had a low discontinuation rate of 3%, indicating good patient retention and adherence to the trial protocol.
Read all positive updates
Company Guidance
During the Q1 2024 earnings call for GlycoMimetics, the management provided updates on the Phase III study of their lead drug candidate, uproleselan, which unfortunately did not achieve a statistically significant improvement in overall survival for patients with relapsed/refractory acute myeloid leukemia (AML). The trial involved 388 patients across 70 sites in 9 countries, with a median overall survival of 13 months for the uproleselan arm and 12.3 months for the placebo arm. Despite not meeting its primary endpoint, the study's unexpected control group survival rate of over one year is considered unprecedented in this setting. The company plans to conduct a comprehensive analysis of the data in collaboration with medical, statistical, and regulatory experts and intends to present findings at a future medical meeting. Additionally, GlycoMimetics highlighted ongoing studies, including a National Cancer Institute-sponsored Phase II/III trial, and mentioned efforts to manage cash burn and revise budget plans as they proceed with further analyses and discussions with the FDA.Crescent Biopharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.84M | 0.00 | 10.00K | 75.00K | 1.16M |
| Gross Profit | 10.76M | -35.17K | 10.00K | 75.00K | 1.16M |
| EBITDA | -149.67M | 0.00 | -39.12M | -47.20M | -63.18M |
| Net Income | -149.94M | -71.47M | -36.90M | -46.69M | -63.43M |
Balance Sheet | |||||
| Total Assets | 240.29M | 35.62M | 45.32M | 51.81M | 94.35M |
| Cash, Cash Equivalents and Short-Term Investments | 213.19M | 34.77M | 41.79M | 47.87M | 90.25M |
| Total Debt | 1.64M | 37.48M | 808.40K | 918.55K | 1.92M |
| Total Liabilities | 37.28M | 51.10M | 6.90M | 8.88M | 12.74M |
| Stockholders Equity | 203.01M | 5.31M | 38.41M | 42.93M | 81.60M |
Cash Flow | |||||
| Free Cash Flow | -72.45M | -31.11M | -34.90M | -46.54M | -57.50M |
| Operating Cash Flow | -71.53M | -31.10M | -34.88M | -46.46M | -57.49M |
| Investing Cash Flow | -72.92M | 20.03K | -21.39K | -84.19K | -14.94K |
| Financing Cash Flow | 322.98M | 5.40K | 28.82M | 4.16M | 10.72M |
Crescent Biopharma Technical Analysis
Positive
18.32
Price Trends
12.07
Positive
12.44
Positive
12.79
Positive
Market Momentum
2.10
Negative
71.98
Negative
83.41
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBIO, the sentiment is Positive. The current price of 18.32 is above the 20-day moving average (MA) of 14.09, above the 50-day MA of 12.07, and above the 200-day MA of 12.79, indicating a bullish trend. The MACD of 2.10 indicates Negative momentum. The RSI at 71.98 is Negative, neither overbought nor oversold. The STOCH value of 83.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBIO.
Crescent Biopharma Risk Analysis
Crescent Biopharma disclosed 68 risk factors in its most recent earnings report. Crescent Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Crescent Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $216.53M | 4.04 | 55.68% | ― | -88.47% | -1658.33% | |
52 Neutral | $249.88M | -3,008.78 | -169.64% | ― | 6.46% | -14.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $504.84M | -8.24 | -122.12% | ― | -100.00% | -0.58% | |
50 Neutral | $137.19M | -0.86 | -55.02% | ― | -46.92% | 20.26% | |
46 Neutral | $73.79M | -1.18 | 9999.00% | ― | -96.91% | 63.11% |
* Healthcare Sector Average
CBIO
Crescent Biopharma
18.32
-1.14
-5.86%
CGEN
Compugen
2.29
1.08
89.26%
FATE
Fate Therapeutics
1.18
0.24
26.20%
OBIO
Orchestra BioMed Holdings
4.27
1.67
64.23%
GUTS
Fractyl Health, Inc.
0.47
-0.48
-51.05%
ACTU
Actuate Therapeutics, Inc.
1.92
-5.19
-73.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.